MedPath

Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD

Phase 4
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Registration Number
NCT01220440
Lead Sponsor
Ostfold Hospital Trust
Brief Summary

The study compares the efficacy of methylphenidate, dextroamphetamine and placebo on neuropsychological functioning and behavioral symptoms in 36 children diagnosed with ADHD within a double-blind cross-over design over six weeks. The assessment of ADHD followed formalized guidelines and a diagnosis of ADHD was based on DSM-IV criteria. A neuropsychological testbattery and four behavioral questionnaires were selected as efficacy variables. The neuropsychological testbattery includes Qb-test (visual attention, inhibitory control, motor activity), Score (auditory attention), Stroop Test (processing speed, inhibitory control) and Grooved Pegboard (motor speed). The participants were tested once on each type of medication. The four questionnaires are: a)Side-Effects Rating Scale (completed by a parent at the end of each of the six weeks), b)Self-Report Questionnaire (completed by the child at the end of each of the six weeks), c)Parent and Teacher Questionnaire(completed by a parent and a teacher Monday till Friday through every week), Test Performance Questionnaire (completed by the child immediately after each of the three test sessions).

Main hypothesis: A trial including both dextroamphetamine(Dex) and methylphenidate(Met) will provide better results than a trial including only Met. a)Met and Dex are efficient as treatment for ADHD compared to placebo, albeit Dex has moderately better effect compared to Met. b)At an individual level some of the participants will show positive response to one type of stimulants and no response, mixed response or adverse response to the other type of stimulant. c)Neuropsychological tests and behavioral questionnaires are moderately in agreement but also add unique information in the assessment of the effect of stimulants. d)Qb-test is sensitive and valid as a measure of the effect of stimulants.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Age from 9.0 to 14.0.
  • ADHD diagnosis following assessment at a child & adolescent outpatient clinic.
  • Clarification for stimulant treatment.
Exclusion Criteria
  • Moderate or severe mental retardation.
  • Psychosis.
  • Proven brain damage.
  • Sensory deficits and/or motor impairments that make the individual in question unsuitable for the relevant tests.
  • Epilepsy.
  • The child has previously been prescribed stimulant medication or is being treated with such medication.
  • The child commutes between parents or there are other factors that substantially reduce the possibility of obtaining reliable observations from parents (The child needs to live in one place through out the whole trial since otherwise might severely influence the child's behaviour and the observations).

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Methylphenidate, Dexamphetamine, PlaceboPlaceboThe 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
Methylphenidate, Dexamphetamine, PlaceboMethylphenidateThe 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
Methylphenidate, Dexamphetamine, PlaceboDextroamphetamineThe 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
Primary Outcome Measures
NameTimeMethod
Change in ADHD and ODD symptomsEvery week for six weeks

Parent and Teacher Questionnaire (completed monday till friday every week) Self-Report Questionnaire (completed once every week) Test Performance Questionnaire (completed by the child after each testsession)

Change in attention, motor activity and executive functioningThe neuropsychological tests are administered once on each type of medication during the six week trial

QB test is a computer based continuous performance test (visual attention and motor activity).

Score!from Test of Everyday Attention - Childrens Edition (auditory attention). C. Golden version of Stroop Test(prosessing-speed and inhibitory control). Grooved Pegboard from the Hallstead battery (motor speed).

Change in side-effectsOnce every week through the six week trial

Side-Effects Rating Scale (R. Barkley)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Ostfold Hospital Neuropsychiatric Unit

🇳🇴

Fredrikstad, Ostfold, Norway

Østfold Hospital Neuropsychiatric Unit

🇳🇴

Fredrikstad, Østfold, Norway

© Copyright 2025. All Rights Reserved by MedPath